Literature DB >> 18504514

Human urine with solifenacin intake but not tolterodine or darifenacin intake blocks detrusor overactivity.

Yao-Chi Chuang1, Catherine A Thomas, Shachi Tyagi, Naoki Yoshimura, Pradeep Tyagi, Michael B Chancellor.   

Abstract

The objective of the study was to evaluate the local effects of three antimuscarinics excreted into human urine after oral ingestion. Two normal adult collected their voided urine after taking oral doses of tolterodine, darifenacin, and solifenacin for 7 days with a 14-day washout period. The urodynamic effect of intravesically administered human urine on carbachol-induced bladder overactivity was studied in female rats. Cystometric parameters were measured during continuous infusion of saline and human urine and then a mixture of carbachol (30 microM) and human urine. Carbachol significantly reduced the intercontraction interval and bladder capacity in the control (urine taken in the absence of oral antimuscarinics) and tolterodine- or darifenacin-administered groups. However, human urine obtained after taking solifenacin prevented the carbachol-induced detrusor overactivity. Urine excreted after oral ingestion of solifenacin provides a localized pharmacological advantage for the treatment of the overactive bladder syndrome.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18504514     DOI: 10.1007/s00192-008-0650-7

Source DB:  PubMed          Journal:  Int Urogynecol J Pelvic Floor Dysfunct


  16 in total

1.  The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society.

Authors:  Paul Abrams; Linda Cardozo; Magnus Fall; Derek Griffiths; Peter Rosier; Ulf Ulmsten; Philip van Kerrebroeck; Arne Victor; Alan Wein
Journal:  Neurourol Urodyn       Date:  2002       Impact factor: 2.696

2.  Antimuscarinic agents exhibit local inhibitory effects on muscarinic receptors in bladder-afferent pathways.

Authors:  YongTae Kim; Naoki Yoshimura; Hitoshi Masuda; Fernando de Miguel; Michael B Chancellor
Journal:  Urology       Date:  2005-02       Impact factor: 2.649

Review 3.  The effects of antimuscarinic treatments in overactive bladder: a systematic review and meta-analysis.

Authors:  Christopher Chapple; Vik Khullar; Zahava Gabriel; Julie Ann Dooley
Journal:  Eur Urol       Date:  2005-03-22       Impact factor: 20.096

4.  A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial.

Authors:  C R Chapple; R Martinez-Garcia; L Selvaggi; P Toozs-Hobson; W Warnack; T Drogendijk; D M Wright; J Bolodeoku
Journal:  Eur Urol       Date:  2005-09       Impact factor: 20.096

5.  Muscarinic receptor subtypes in human bladder detrusor and mucosa, studied by radioligand binding and quantitative competitive RT-PCR: changes in ageing.

Authors:  Kylie J Mansfield; Lu Liu; Frederick J Mitchelson; Kate H Moore; Richard J Millard; Elizabeth Burcher
Journal:  Br J Pharmacol       Date:  2005-04       Impact factor: 8.739

Review 6.  Antimuscarinic drugs in detrusor overactivity and the overactive bladder syndrome: motor or sensory actions?

Authors:  Steven M Finney; Karl-Erik Andersson; James I Gillespie; Laurence H Stewart
Journal:  BJU Int       Date:  2006-09       Impact factor: 5.588

7.  Augmented extracellular ATP signaling in bladder urothelial cells from patients with interstitial cystitis.

Authors:  Yan Sun; Toby C Chai
Journal:  Am J Physiol Cell Physiol       Date:  2005-08-17       Impact factor: 4.249

Review 8.  Muscarinic receptor antagonists for overactive bladder.

Authors:  Paul Abrams; Karl-Erik Andersson
Journal:  BJU Int       Date:  2007-11       Impact factor: 5.588

9.  Effects of the M3 receptor selective muscarinic antagonist darifenacin on bladder afferent activity of the rat pelvic nerve.

Authors:  Kazuyoshi Iijima; Stefan De Wachter; Jean-Jacques Wyndaele
Journal:  Eur Urol       Date:  2007-03-06       Impact factor: 20.096

Review 10.  Antimuscarinics and the overactive detrusor--which is the main mechanism of action?

Authors:  K-E Andersson; M Yoshida
Journal:  Eur Urol       Date:  2003-01       Impact factor: 20.096

View more
  5 in total

Review 1.  Safety and tolerability profiles of anticholinergic agents used for the treatment of overactive bladder.

Authors:  Michael G Oefelein
Journal:  Drug Saf       Date:  2011-09-01       Impact factor: 5.606

Review 2.  Urothelial effects of oral agents for overactive bladder.

Authors:  Karl-Erik Andersson; Claudius Fullhase; Roberto Soler
Journal:  Curr Urol Rep       Date:  2008-11       Impact factor: 3.092

3.  Urine: Waste product or biologically active tissue?

Authors: 
Journal:  Neurourol Urodyn       Date:  2018-02-21       Impact factor: 2.696

4.  Functional role of cannabinoid receptors in urinary bladder.

Authors:  Pradeep Tyagi; Vikas Tyagi; Naoki Yoshimura; Michael Chancellor
Journal:  Indian J Urol       Date:  2010 Jan-Mar

Review 5.  Intravesical liposome and antisense treatment for detrusor overactivity and interstitial cystitis/painful bladder syndrome.

Authors:  Pradeep Tyagi; Mahendra P Kashyap; Naoki Kawamorita; Tsuyoshi Yoshizawa; Michael Chancellor; Naoki Yoshimura
Journal:  ISRN Pharmacol       Date:  2014-01-15
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.